Analyst Price Target is $9.50
▲ +73.99% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alimera Sciences in the last 3 months. The average price target is $9.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 73.99% upside from the last price of $5.46.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Alimera Sciences. This Buy consensus rating has held steady for over two years.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.